Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., said it intends to offer 8 million shares of its common stock in a proposed underwritten public offering. No terms have yet been set. Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering.

Arrowhead Research Corp., of Pasadena, Calif., said it closed an underwritten offering of 6.325 million shares of common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 825,000 shares at the offering price of $18.95 per share. Gross proceeds of the transaction were approximately $120 million.

Benitec Biopharma Ltd., of Sydney, Australia, said it completed a private placement of up to approximately 29.4 million of the company’s ordinary shares at A$1.07 each, raising approximately A$31.5 million (US$28.5 million) from international institutional investors. The company has also agreed to issue the investors free attaching options to purchase up to an additional 13.2 million ordinary shares at an exercise price of A$1.26 per ordinary share, to expire in five years. Proceeds from the private placement will be used to accelerate clinical development of lead compound TT-034, a potential single shot treatment for hepatitis C. Funds will also be used to advance other programs in the company’s pipeline, with a particular emphasis on the lung cancer, age-related macular degeneration and hepatitis B programs. The placement was managed by U.S. investment bank Maxim Group LLC and Lodge Corporate Pty Ltd. in Australia.